CRISPR and genetics join to personalize psychotropic drugs

Researchers are exploring a novel way to personalize psychiatric medications by combining CRISPR gene-editing technology with pharmacogenetics that accounts for genetic ancestry. This approach aims to improve how drugs like antidepressants and antipsychotics work for people of different backgrounds, especially in Brazil, where the population is highly diverse. The review discusses how integrating these tools could help predict which medications are most effective and safe for individuals based on their unique genetic makeup. However, this is a review of early-stage concepts, not a clinical trial. No specific results or safety data are reported, and the approach has not been tested in patients yet. The main takeaway is that this is a promising direction for future research, but it is not ready for use in clinics. Readers should understand that personalized psychotropic treatment based on CRISPR and ancestry is still in the theoretical and experimental phase.